Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
09 August 2016
Syndax Pharmaceuticals (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the second quarter ended June 30, 2016 and provided a pipeline update as well as a review of upcoming milestones. As of June 30, 2016, Syndax had $125.5 million in cash, cash equivalents and short-term investments.
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results
09 August 2016
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and announced its financial results for the second quarter ended June 30, 2016.
Miramar Labs’ miraDry System Featured in Cover Story in The Aesthetic Guide
03 August 2016
Miramar Labs, Inc., (OTCQB: MRLB), a global aesthetic company, announced today that the Company’s miraDry® system is featured in a cover story in the July/August edition of The Aesthetic Guide. The miraDry system delivers microwave energy to non-invasively destroy sweat and odor glands in the underarm, and is also approved for permanent hair removal of the underarm. The cover story article, titled “Miramar Labs Creates New Markets with miraWave Therapy,” may be accessed on-line in the current issue of the magazine.
01 August 2016
ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces clinical results indicating that structural changes induced by the corneal shape-changing Raindrop Near Vision Inlay leads to significantly improved near and intermediate vision in subjects with presbyopia, with no loss of distance binocular acuity.
01 August 2016
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that Glenn Noronha , Ph.D., has been promoted to Chief Scientific Officer and Jennifer M. Kissner , Ph.D., has been promoted to Vice President, Clinical Development. Both Drs. Noronha and Kissner will assume their roles immediately and will report to Daniel H. White , CEO and President of Clearside Biomedical .
Syndax Appoints Leading Experts to Scientific Advisory Board (SAB)
27 July 2016
Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, today announced that it has entered into an exclusive worldwide license agreement with UCB for UCB6352, an IND-ready anti-CSF-1R monoclonal antibody, which is expected to begin clinical trials in 2016.
26 July 2016
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today reports additional top-line data from its Phase 2 clinical trial (TANZANITE). 78% of Patients Required No Additional Treatment in the Trial Arm with Concomitant Suprachoroidally Administered Zuprata™ and Intravitreally Administered Eylea®.
ReVision Optics Appoints Frank Shields Vice President of Sales Worldwide
25 July 2016
ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces the appointment of Frank Shields to the newly created position of Vice President of Sales Worldwide effective immediately. Mr. Shields brings more than 25 years of experience in surgical sales at leading ophthalmic companies and has been instrumental in the launch of several leading ophthalmic lens products. He will be responsible for leading the commercialization of the Raindrop Near Vision Inlay in the U.S. and expanding international sales.
Ferring announces data from its Phase III ESTHER trials
12 July 2016
Ferring Pharmaceuticals have announced data from their ESTHER trials at the Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE).
07 July 2016
Genomic Health, Inc. (GHDX) and Epic Sciences, Inc. today announced an exclusive agreement to commercialize Epic Sciences' novel AR-V7 liquid biopsy test in the United States through Genomic Health's world-class commercial channel. The blood-based test detects the V7 variant of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells (CTC) – information that can help guide treatment selection in patients with metastatic castration-resistant prostate cancer (mCRPC).
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024